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When studying patient specific induced pluripotent stem cells (iPS cells) as a disease model, the ideal control is
an isogenic line that has corrected the point mutation, instead of iPS cells from siblings or other healthy subjects.
However, repairing a point mutation in iPS cells even with the newly developed CRISPR-Cas9 technique remains
difficult and time-consuming. Here we report a strategy that makes the Cas9 “knock-in” methodology both
hassle-free and error-free. Instead of selecting a Cas9 recognition site close to the point mutation, we chose a site
located in the nearest intron. We constructed a donor template with the fragment containing the corrected point
mutation as one of the homologous recombination arms flanking a PGK-PuroR cassette. After selection with
puromycin, positive clones were identified and further transfected with a CRE vector to remove the PGK-PuroR
cassette. Using this methodology, we successfully repaired the point mutation G2019S of the LRRK2 gene in a
Parkinson Disease (PD) patient iPS line and the point mutation R329H of the AARS1 gene in a Charcot-MarieTooth disease (CMT) patient iPS line. These isogenic iPS lines are ideal as a control in future studies.

1. Introduction
About half of the known human pathogenic genetic variants are
point mutations (Anzalone et al., 2019) in which the disease gene only
has one nucleotide difference in patients compared with that of healthy
individuals. Thus, a strategy which uses an easy and reliable way to
correct point mutations would represent a significant step forward.
Recent developments in gene targeting techniques, especially CRISPRCas9, makes routine the repair of these genetic mutations (Protocols
like in (Ran et al., 2013)). In such applications, synthesized singlestranded oligodeoxynucleotides (ssODN) as donor templates are most
commonly used in homology-directed repair-based (HDR) knock-in for
small repairs (Richardson et al., 2016). The knock-in efficiency has been
shown to be higher when using ssODNs with the introduction of a silent
mutation at the PAM site to prevent cutting on the edited allele (Arm
strong et al., 2016). Also using asymmetric donor DNA can increase the
HDR efficiency (Richardson et al., 2016). However, several obstacles
still remain. First, finding suitable Cas9 cleavage sites is not always
practical. The conventional CRISPR-Cas9 “knock-in” strategy usually
requires that the selected cleavage site resides as close as possible to the
mutation site to achieve higher efficiency (Bialk et al., 2015; Harmsen

et al., 2018; Paquet et al., 2016). Secondly, while double-strand
breakage has a higher efficiency of HDR than single-strand nicks,
many non-homologous end joining (NHEJ) events happen during
double-strand breakage. Moreover, using synthesized ssODN with short
homologous arms produces more occurrences of insertions and deletions
(indels) or point mutations compared to plasmid donor templates with
long homologous arms (Elliott et al., 1998). Most critically, the effi
ciency of homologous repair is still low even with the latest development
of RNP (ribonucleoprotein: synthetic sgRNA and Cas9 recombinant
protein complex) (Okamoto et al., 2019) when there is no reporter or
selection cassettes. Finally, in order to identify positively targeted
clones, it is necessary to sequence the genomic components of a large
number of clones.
To repair point mutations more efficiently, the Liu lab first developed
the base editor using a catalytically impaired Cas protein (dCas or Cas
nickase) connected with a DNA-modifying enzyme, a deaminase to make
precise base substitution possible. After sgRNA directs dCas to the target
site, without double-strand cleavage or donor template DNA, the
deaminase modifies the base instead of Cas9 cleavage of the DNA
(Komor et al., 2016). Current base editing techniques only allow base
substitutions of C•G to T•A that is mediated by cytosine base editors
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(CBEs), and base substitutions of A•T to G•C that is mediated by adenine
base editors (ABEs). Consequently, the speed of base editing can be slow
and the selection of the targeted site limited.
Here, we apply the CRISPR-Cas9 technique to generate an isogenic
line from the most common variant of LRRK2 gene in both familial and
idiopathic PD patients (Goldwurm et al., 2005). This c.6055G > A point
mutation changes Gly to Ser at 2019aa, increasing kinase activity of
LRRK2 (West et al., 2005). It remains unclear why this activated form of
LRRK2 is tightly associated with PD. In the last decades, iPS cell tech

extracted from iPS cells of normal subject. Subsequently, they were
cloned into the human Oct4-GFP vector (Addgene Plasmid #21153)
replacing the Oct4-L arm-2A-GFP and Oct4-R arm and were sequenced
to confirm correct amplification and connection. All cloning primers are
listed below. The underlined nucleotides of LRRK2-R arm primers are
the restriction enzyme recognition sites. The other three arms were
cloned using NEB Hi-Fi DNA Assembly kit (New England Biolabs) due to
the lack of suitable restriction enzyme sites. The underlined nucleotides
therein marked the sequences of the vector.

Fragment Name

Forward Primer Sequence

Reverse Primer Sequence

LRRK2-L arm
LRRK2-R arm
AARS1-L arm
AARS1-R arm

caagcttggtaccgagctcgCCTTAATATCTAACATGATTAGGTTTATG
TTTATTGGCGCGCCCAGGATGGATAACCACTGAC
caagcttggtaccgagctcgAATGGCCCGATCTTGGCTC
cctcgaagaggttcactaggGGGTAGGATTCCAAGGGAC

gggttattgaatatgatcggAAGATAGAATTATGAGACAGAC
TTTATTGCGGCCGCTCCCTAAAGATAGAGTGTTCC
gggttattgaatatgatcggAAGCAACACCTCTTTCAGGAAC
ctctagatgcatgctcgagcTCTGTCAGAAAGGGCTTG

nology brought about a revolutionary change in human disease
modeling. Thus, with the introduction of a combination of 3 or 4 tran
scription factors, somatic cells can be transformed into stem cells with
unlimited capacity for cell division and differentiation (Takahashi et al.,
2007). Reprogrammed patient cells can be used to explore disease
mechanisms or screen for possible useful drug therapies. In these
studies, the use of control isogenic cell lines derived from the same
patient iPS cells is critical. Instead of designing the sgRNA recognition
site close to the mutation site, we chose a location in the nearest intron
that gives more flexibility to choose an optimal sgRNA location. Having
the corrected sequence on one of the homologous arms, the mutated
allele was repaired through homologous recombination. We also
included a loxP flanked PGK-PuroR cassette so that after selection with
puromycin, the efficiency of choosing positive clones would be much
higher. With this new efficient strategy, we successfully obtained clones
that have corrected the point mutation. Similarly, using this same gene
editing strategy, we also efficiently repaired the c.986G > A point mu
tation of AARS1 gene, which changes Arg to His at 329aa in familial
CMT patients (McLaughlin et al., 2012). The AARS1 gene codes for the
growth-dependent essential enzyme alanyl-tRNA synthetase, which
catalyzes aminoacylation of tRNAAla with alanine to support translation
of alanine codons during protein synthesis on the ribosome. The R329H
mutation of AARS1 severely compromises the catalytic activity of the
enzyme (McLaughlin et al., 2012), emphasizing the importance to study
this mutation in the development of the CMT disease.

2.3. Gene targeting in hiPSCs
A million of LRRK2 or 100550A iPS cells were harvested using
Accutase (Sigma) and reverse-transfected with 1 μg of donor construct,
12 pmol spCas9 protein (Aldevron), and 18 pmol of sgRNA (LRRK2: 5′ GAACTCACATCTGAGGTCAG-3′ ,
AARS1:
5′ -GGGCGTATCGGA
CAGCTCGG-3′ , Synthego), 4 μl P3000 reagent and later with 5 μl Lip
ofectamine 3000 (Thermo-Fisher). A mixture of transfection reagents
was added onto a Cultrex-coated well first and then followed by resus
pended LRRK2 iPS cells or 100550A iPS cells in fresh medium with 5 μM
Y-27632 (Stemgent). Puromycin (500 ng/ml, Sigma) was added into the
medium three to five days after transfection. Drug-resistant cells were
replated at low density (5,000 cells/100 mm dish) and single cell col
onies were manually selected afterwards. Clones with both 5’ and 3’
insertion positive genotyping results were further expanded and the
puromycin cassette was deleted by transient transfection of a CRE vector
pCAG-Cre:GFP (Addgene #13776) and then plated at low density for
single cell colonies. After a 2nd round of genotyping, positive clones
were expanded and characterized.
2.4. Genotyping
Cells were collected and treated with 1x lysis buffer in PBS (For 4x
stock: Tris-HCl pH 8 (10 mM), Triton X (2%), EDTA (4 mM) and freshly
added Proteinase K (1%)) at 60 ◦ C for 1 hr followed by 95 ◦ C for 10 min.
Genotyping was done using 1 μl of the lysis mixture as templates and two
sets of primers to confirm both the 5′ insertion and the 3′ insertion at the
first round. Primer set LRRK2-P1, AARS1-P1 and Puro-pA-R-P10 were
used for confirmation of the 5′ insertion. Primer set Puro-pA-P3-2 and
LRRK2-P4, AARS1-P4 were used for confirmation of the 3′ insertion. A
primer set P1 and P6 was used to distinguish between WT (946 bp) and
targeted alleles (1042 bp) at the second round of LRRK2 targeting. The
genomic DNA amplified by the primer set LRRK2-P5 and LRRK2-P6 was
sent for sequencing. Primer set of AARS1-P5 and AARS1-P6 was used to
distinguish between WT (189 bp) and targeted alleles (275 bp) at the
second round of AARS1 targeting.

2. Materials and methods
2.1. Cell culture
LRRK2 (ND40018*C) iPS cell line was obtained from NINDS human
genetics DNA and cell line repository. Fibroblasts harboring the R329H
AARS1 mutation were isolated from an anonymous patient in Australia
through clinical collaboration with Dr. Michael Shy of University of
Iowa, and were made into 100550A iPS cell line with mRNA reprog
ramming kit (Stemgent). BJ fibroblast were obtained from ATCC (CRL2522™) and reprogrammed with the same mRNA reprogramming kit.
LRRK2 and BJ iPS cells were maintained in mTeSR1 medium (Stem Cell
Technologies) and 100550A iPS cells were kept in Stemflex medium
(Thermo-Fisher) at 37 ◦ C in a 5% CO2 incubator. Cells were passaged
using 0.5 mM EDTA and replated onto Cultrex (1:100 diluted in DMEM/
F12, Biotechne)-coated plates.
2.2. Construction of donor plasmids
For generating LRRK2-PGK-Puro and AARS1-PGK-Puro vectors, two
pairs of homologous arms, LRRK2-L and LRRK2-R arms, and AARS1-L
and AARS1-R arms, were amplified from human genomic DNA
2

Primer Name

Primer Sequence

LRRK2-P1
Puro-pA-P3
Puro-pA-P3-2
LRRK2-P4
LRRK2-P5
LRRK2-P6
Puro-pA-R-P10
AARS1-P1
AARS1-P4
AARS1-P5
AARS1-P6

ATTGCGTGGGTCAGTCTC
GCAGCCTCTGTTCCACATAC
CCCTCGAAGAGGTTCACTAG
AGCAAGATGATGTATAGCCACC
TAAGGGACAAAGTGAGCACAG
ATCTGAGGTCAGTGGTTATCC
GACGTAAACTCCTCTTCAGACC
ACGTAGCTGGGATTATAGGTG
CAGAGACATGAGAGCCCAC
TGACCTTGGGGAATGCGAAA
TTCATGGGCGTATCGGACAG
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Fig. 1. A stress-free strategy of correcting point mutations in patient iPS cells. A, Schematic representation of the strategy to generate a LRRK2 isogenic line with the
corrected allele (correction of the c.6055G > A mutation of LRRK2 gene). B, Schematic representation of the strategy to generate a 100550A isogenic line with the
corrected allele (correction of the c.986G > A mutation of AARS1 gene).

2.5. QX200 Droplet Digital PCR (ddPCR™, BIO-RAD)

both isogenic and parental 100550A lines (PTX4-F2: ATCCACTTCGT
GATCGGGGA; PTX4-R2: GCCCTTGCTGGCCTCAG). Then the amplicons
were sequenced to investigate any changes for those areas.

Genomic DNA was purified from each targeted 100550A cell sample
with QIAamp DNA Mini Kit (Qiagen). A 20 µl PCR reaction mixture
containing 50–100 ng genomic DNA, primer and probe set (designed by
BIO-RAD, Cat# 10049047, Project dHsaMDS305174770), and QX200™
ddPCR™ Supermix for probes (no dUTP) (BIO-RAD) were used for
droplet generation. Emulsified samples were then transferred to PCR
plates according to manufacturer’s instructions. The cycling protocol
was used with a 95 ◦ C enzyme activation step for 5 min followed by 40
cycles of a two-step cycling protocol (95 ◦ C for 30 s and 55 ◦ C for 1
min). The ramp rate between these steps was 2 ◦ C/second. The post
cycling step of enzyme deactivation was set at 98 ◦ C for 10 min with the
ramp rate 1 ◦ C/second. After PCR reaction, the plate was put in the
QX200™ Droplet Reader and the events were recorded using the pro
gram QuantaSoft.

2.7. Immunocytochemistry
Undifferentiated isogenic iPSCs were fixed with 4% para
formaldehyde in 1x PBS for 20 min and blocked with 1% (v/v) bovine
serum albumin (Sigma), 0.2% (v/v) Triton-X (SigmaAldrich), 5%
normal donkey or goat serum in 1 × PBS for 30 min. They were then
incubated with primary antibodies overnight at 4 ◦ C, and subsequently
labeled with fluorescence-conjugated secondary antibodies for 1 h. Im
ages were acquired using a fluorescence microscope (Olympus Optical,
JP/IX-71).
2.8. STR analysis
Short tandem repeat (STR) analysis was performed on generated
isogenic LRRK2 and 100550A clones, together with their parental clones
using the PowerPlex®16 System (Promega) with the detection of 16
allele loci at the Molecular & Genomic Pathology Laboratory of Thomas
Jefferson University Hospital.

2.6. Off-targeting analysis
LRRK2 and AARS1 sgRNA sequences were submitted to the website
http://www.rgenome.net/cas-offinder/ to search for possible offtargeting human genomic positions with the threshold of 4 mis
matches. All resultant genomic fragments (217 for LRRK2 and 11 for
AARS1) were then blasted to the database: Human genomic plus tran
script (Human G + T) at https://blast.ncbi.nlm.nih.gov/Blast.cgi. There
was only one DNA fragment (similar to LRRK2) matching the coding
area of human transcripts ANXA9 and one DNA fragment (similar to
AARS1) matching the coding area of human transcripts PTX4. The cor
responding genomic region of ANXA9 was amplified by the primers from
both isogenic and parental LRRK2 lines (ANXA9-F: CCGTGATGG
TACTTGTGCCT; ANXA9-R: CATCTTATGTGCATGGCGGC). The corre
sponding genomic region of PTX4 was amplified by the primers from

3. Results and discussion
3.1. Cas9 and sgRNA can target the LRRK2 locus in the LRRK2 iPS line
and AARS1 in the 100550A iPS line
In order to correct the point mutation c.6055G > A of the LRRK2
gene and c.986G > A of the ARRS1 gene, we chose the Cas9 recognition
site in the intron closest to each mutation. For LRRK2 gene, it was in the
intron after the exon containing the mutation. For ARRS1 gene, it was in
3
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Fig. 2. Correction of the c.6055G > A mutation in
LRRK2. A, Genotyping results of 48 LRRK2 isogenic
clones after CRE cleavage of the PGK-PuroR cassette.
The PCR primer set P1 + P6 was used to amplify the
region covering the exon and the cutting area of the
intron. When one allele was edited, the remaining
loxP site made the amplicon (1042 bp) larger than
that of the unedited allele (946 bp). The genotyping
PCR was performed with 57 ◦ C annealing tempera
ture, 35 cycles and 1 min for extending step. The
clone numbers are labeled for those clones having
both alleles targeted, which expressed as one single
up-shifted band. N marks untargeted LRRK2 cells
expressing only the untargeted band as a negative
control. B, Sequencing results of the G > A mutation
area of a homozygous LRRK2 isogenic clone 4 line
(top row). BJ line, an iPS cell line from a healthy
subject with the WT LRRK2 gene was used as a pos
itive control (middle row). An unedited LRRK2
parent line was used as a negative control (bottom
row). The arrows are pointing to the nucleotide of
interest.
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org/gpp/public/analysis-tools/sgrna-design). Fig. 1 describes our tar
geting strategy for correcting the point mutation using Cas9-mediated
homologous recombination. The donor template contains the cor
rected LRRK2 gene fragments (A) or the corrected AARS1 gene frag
ments (B) amplified from a normal subject iPS line, BJ, spanning the
pGK-PuroR cassette. Following sequencing analysis and confirmation of
the successful cloning of donor template, the RNP and donor template
was reverse transfected into the LRRK2 or 100550A iPS cells with Lip
ofectamine 3000. After puromycin selection, surviving cells were gen
otyped. Nine of 45 LRRK2 clones showed positive for both the 5′
insertion (P1 + P10) and the 3′ insertion (P3-2 + P4) (Data not shown).
These successful gene targeted clones were pooled together and were
further transfected with a CRE vector pCAG-Cre:GFP to remove the se
lection cassette. Then single cell colonies were manually selected and
genotyped for the second time. From the screening results of PCR with
primers P1 and P6, 13 of the 48 clones exhibited only an up-shifted
band, indicating positive gene targeting of both alleles (Fig. 2A). After
sequencing each of these up-shifted bands, we successfully confirmed
that the correction of both alleles was made in these LRRK2 isogenic
clones (Fig. 2B). Fifteen of 47 100550A clones demonstrated positive for
the 3′ insertion (P3-2 + P4) (Fig. 3A). In contrast to the LRRK2 isogenic
cells, the 100550A isogenic clones only contained one allele targeted
while the other allele unaffected. Consistently, PCR screening with
primer set P5 + P6 revealed no single band in each clone tested (Fig. 3B).
To further confirm that the mutation was repaired, genomic DNA from
the positive clones was purified and analyzed using ddPCR primers and
two probes detecting either wild type or mutant alleles. Indeed, two
clones tested showed no mutant allele (Fig. 3C), indicating that the
mutation had been corrected to the WT sequence.
The confirmed LRRK2 isogenic clones (Fig. 4 A-D) and 100550A
isogenic clones (data not shown) were evaluated for pluripotency
markers including Oct3/4, Sox2, Nanog, and SSEA-4 to confirm their
cell stemness. The results showed that these isogenic clones maintained
expression of their pluripotency markers. In addition, the genomic DNA
of LRRK2 isogenic clone 4 and 100550A isogenic clone 9, together with
that of the respective parent lines, was sent for Short Tandem Repeat
(STR) analysis. The genomic DNA of both isogenic clones exhibited the
same patterns for all sixteen markers examined as those of their
respective parent lines (Fig. 4E), demonstrating that both lines of
isogenic clones originated from the respective parent iPS lines. We
checked both LRRK2 and AARS1 sgRNA for potential off-targeting
events on the website http://www.rgenome.net/cas-offinder/. The re
sults returned with 16 genomic regions of 3-mismatches and 201 of 4mismatches for LRRK2 sgRNA, one 3-mismatch and ten 4-mismatches
for AARS1 sgRNA. After blasting all resultant DNA sequences at NCBI,
we found only one match (LRRK2 sgRNA sequence) to the coding area of
ANXA9 gene and one match (AARS1 sgRNA sequence) to the coding area
of PTX4 gene. The majority of other genomic DNA regions were not
matching to any human transcripts with the exception of a couple of
DNA sequences found on some transcripts but outside the coding area
(Excel file submitted as Supplementary data). With specific primers, we
amplified the matching ANXA9 region from both LRRK2 isogenic and
parental iPS lines and the matching PTX4 region from both 100550A
isogenic and parental iPS lines. After sequencing all 4 DNA fragments,
we found no changes in the area of ANXA9 gene or PTX4 gene
(Figure Supplementary figure 1, Figure Supplementary figure 2). Thus,
we concluded that off-targeting events were not of major concern in
either isogenic line.

Fig. 3. Correction of the c.986G > A mutation in AARS1. A, Genotyping results
of 47 100550A clones after puromycin selection. Using the PGK-PuroR cassette
specific primer P3-2, the clones with the amplified band (915 bp, as shown)
were the targeted clones. Pooled cells after selection were used as a positive
control (+). This genotyping PCR was performed with 55 ◦ C annealing tem
perature, 35 cycles and 1 min for extending step. B, Genotyping results of 5
positive clones (Clone No: 1, 6, 7, 9, 11) after CRE removal. P5 + P6 amplifi
cation produced two bands in each of the 5 clones, all of which were hetero
zygotes with one targeted allele and one untargeted allele. Negative (N) control
was unedited 100550A iPS cells. This genotyping PCR was performed with
55 ◦ C annealing temperature, 35 cycles and 30 s for extending step. C, Geno
typing of 2 clones using ddPCR. There were only amplification from wild type
primer set and probe in Clone 6 (C6) and Clone 9 (C9). Unedited 100550A iPS
cells were used as a positive control, showing a similar positive number of
events of both wild type and mutant AARS1 gene. HEK293 cells were used as a
negative control for mutant AARS1 gene.

3.2. A more efficient way for knock-in gene targeting
We had previously attempted to use the conventional ssODN and
RNP approach to repair point mutations in iPS cells. Because Cas9
editing efficiency was tightly correlated with the mutation site, we had
to choose a sgRNA in the same exon, ideally as close as possible to the
mutation site. This largely limited the choices of sgRNA. To identify

the intron in front of the exon. To design the sgRNA, the first 100 bp of
the intron in human LRRK2 gene or the last 100 bp of the intron of
AARS1 gene was analyzed to identify suitable target sites using the
designing tool from Broad Institute (https://portals.broadinstitute.
5
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Fig. 4. Characterization of restored isogenic cells. A, an LRRK2 isogenic colony shows smooth boundary, the typical morphology of a colony of undifferentiated cells.
B,C, The cells in the colony are all positive for stem cell surface markers SSEA4 and TRA-1–60 when stained with the marker for each in live-cell imaging. D, All cells
in the colony are also positive for stem cell nuclear markers Oct4 and Nanog when stained after fixation. All four stem cell markers were uniformly expressed in
individual cells. E, The STR analysis shows that the marker patterns of LRRK2 isogenic clone 4 perfectly match with those of the parental LRRK2 line, while the
marker patterns of isogenic clone 9 match with those of its parent 100550A line.

compared to the traditional approach for knock-in gene targeting, this
new strategy provides the possibility of antibiotic selection, flexibility of
sgRNA design, avoids possible NHEJ events and therefore has the po
tential to advance the use of iPS lines as disease models.

Table 1
comparison of the gene editing efficiencies (AARS1 gene) from traditional
method and new strategy described in this manuscript.

Single cell clone tested No.
Edited clone No. (PCR
analysis)
Editing rate
Confirmed clones
(sequencing or ddPCR)
Success rate

Traditional ssODN and
RNP method

New donor vector and
RNP method

96
4

47(after CRE transfected)
15

4.2%
0

31.9%
2 out of 5 (after CRE
vector transfected)
40%

0%
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positive clones, we needed to introduce a silent mutation to construct a
restriction enzyme site for the subsequent characterization when
designing ssODN. In addition, genotyping hundreds of clones and per
forming restriction enzyme reactions was tedious and time-consuming.
Despite having screened hundreds of clones, we found only a couple
of positive clones, all of which contained undesired additions or de
letions at the Cas9 cleavage site causing frameshifting of the reading
frame. We have thus developed this new strategy, which yields a much
higher positivity rate due to the ability to engage an antibiotic selection
(Table 1). In addition, the flexibility of the Cas9 cleavage location also
provides a greater chance of selecting a more efficient sgRNA. Because
Cas9 enzyme cleavage in this method occurs in an intron, we were able
to avoid potential NHEJ events interfering with exon expression. The
sequencing result from LRRK2 isogenic clones also showed that the
corrected exon has no frameshifting or other mutations. We note that
this same strategy is successful with the two targeted genes, even though
LRRK2 isogenic lines have both alleles targeted while 100550A isogenic
lines have only one allele targeted. Targeting efficiency may be further
improved by varying the concentration of puromycin, the starting time
of puromycin treatment after transfection, and the sequence context for
designing sgRNA cleavage. It is mere coincidence that mutations in our
two patient-derived iPSC lines are both G > A. Since the correction is
introduced on a homologous arm, we predict that this strategy should
work in other point mutations or frameshifting. It is noteworthy that our
two mutations happen to be relatively close to a nearby intron making it
possible to find a specific and efficient gRNA for Cas9 cutting. For mu
tations of intronless coding regions or mutations where no nearby in
trons can be found, our method will probably not work. In conclusion,
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